Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits.

Abstract

BACKGROUND:

We aimed to study the inhibitory effects of topical cyclosporine A (CsA) 0.05% on immune-mediated corneal neovascularization, and to compare its efficacy with those of dexamethasone 0.1% and bevacizumab 0.5%.

METHODS:

Immune-mediated corneal neovascularization was created in 36 right eyes of 36 rabbits. The rabbits were then randomized into four groups. Group I received CsA 0.05%, Group II received dexamethasone 0.1%, Group III received bevacizumab 0.5%, and Group IV received isotonic saline twice a day for 14 days. The corneal surface covered with neovascular vessels was measured on the photographs. The rabbits were then sacrificed and the corneas excised. Paraffin-embedded sections were stained with hematoxylin-eosin and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay.

RESULTS:

The means of percent area of corneal neovascularization in Group I, II, III, and IV were 24.4%, 5.9%, 37.1%, and 44.1%, respectively. The inhibitory effect of CsA 0.05% was found to be better than the effect found in the bevacizumab 0.5% and control groups (p = 0.03 and p = 0.02, respectively). CsA 0.05% was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1% (p < 0.001). Apoptotic cell density was higher in Group III and Group IV than in Group I and Group II. There was no difference between Group I and Group II in terms of apoptotic cell density (p = 0.7).

CONCLUSIONS:

Topical CsA 0.05% was shown to have an inhibitory effect on immune-mediated corneal neovascularization in rabbits.

• Authors: Yasin Yücel Bucak, Mesut Erdurmus, Elçin Hakan Terzi, Aysel Kükner, Serdal Çelebi
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 251 Issue 11 Pg. 2555-61 (Nov 2013) ISSN: 1435-702X [Electronic] Germany
• PMID: 24048578 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 5-(3-(1-(5-(5-(biotinylamino)pentanamidomethyl)-2-nitrophenyl)ethoxycarbonylamino)propenyl)-2'-deoxyuracil 5'-triphosphate
• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Deoxyuracil Nucleotides
• Glucocorticoids
• Immunosuppressive Agents
• Ophthalmic Solutions
• Serum Albumin, Bovine
• Bevacizumab
• Biotin
• Dexamethasone
• Cyclosporine

Topics

• Administration, Topical
• Angiogenesis Inhibitors (administration & dosage)
• Animals
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Apoptosis
• Arthus Reaction (drug therapy, immunology)
• Bevacizumab
• Biotin (analogs & derivatives)
• Corneal Neovascularization (drug therapy, immunology)
• Cyclosporine (administration & dosage)
• Deoxyuracil Nucleotides
• Dexamethasone (administration & dosage)
• Disease Models, Animal
• Glucocorticoids (administration & dosage)
• Immunoenzyme Techniques
• Immunosuppressive Agents (administration & dosage)
• In Situ Nick-End Labeling
• Ophthalmic Solutions
• Rabbits
• Serum Albumin, Bovine (immunology)